Dry eye disease (DED) is a chronic, inflammatory, and highly heterogeneous condition of the eye; it is also referred to as dry eye syndrome or keratoconjunctivitis sicca. Although DED represents a large prevalent pool in the G7 markets, the condition is underdiagnosed and few drugs are approved to treat it. As such, commercial opportunity abounds in this space. Indeed, despite the challenges in drug development for DED, the pipeline is robust, with a number of drugs in active late-phase development. With the expected launch of six new drugs for DED and the generic entry of AbbVie’s blockbuster Restasis in the United States, the DED therapy market is set to be dynamic and competitive over the next decade.
Geographies: United States, EU5, Japan.
Primary research: 20 country-specific interviews with thought-leading ophthalmologists and optometrists. Supported by survey data collected for this and other DRG research.
Epidemiology: Total prevalence of DED by country, including diagnosed prevalence and prescription drug-treatment rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key therapies for DED through 2029, segmented by brands / generics.
Emerging therapies: Phase III: 7 drugs; coverage of select Phase II drugs.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.